Trial Information
An Assessment of the Calcimimetic Agent AMG 073 for the Treatment of Subjects With Parathyroid Carcinoma or Intractable Primary Hyperparathyroidism.
Inclusion Criteria
- Patients must have parathyroid carcinoma or severe primary hyperparathyroidism; *
Abnormally elevated calcium levels above 12.5 mg/dL; * Not be pregnant or nursing; *
Not have had any type of cancer other than parathyroid carcinoma within the last 5
years.
Type of Study:
Interventional
Study Design:
Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
Changes in serum calcium and PTH
Principal Investigator
MD
Investigator Role:
Study Director
Investigator Affiliation:
Amgen
Authority:
United States: Food and Drug Administration
Study ID:
20000204
NCT ID:
NCT00037518
Start Date:
April 2001
Completion Date:
Related Keywords:
- Hyperparathyroidism
- Parathyroid Neoplasms
- Severe primary hyperparathyroidism
- Parathyroid carcinoma
- Neoplasms
- Hyperparathyroidism
- Parathyroid Neoplasms
- Hyperparathyroidism, Primary